CVS Health (CVS) Expected to Announce Earnings on Wednesday

CVS Health (NYSE:CVS) will likely be announcing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect CVS Health to post earnings of $1.86 per share and revenue of $100.0886 billion for the quarter. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Interested persons may review the information on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. The company had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm’s revenue for the quarter was up 6.2% on a year-over-year basis. During the same period in the prior year, the company posted $2.25 EPS. On average, analysts expect CVS Health to post $7 EPS for the current fiscal year and $8 EPS for the next fiscal year.

CVS Health Stock Up 2.2%

Shares of CVS Health stock opened at $109.41 on Wednesday. CVS Health has a 1-year low of $58.99 and a 1-year high of $110.68. The company has a market capitalization of $139.59 billion, a PE ratio of 48.20, a P/E/G ratio of 1.05 and a beta of 0.61. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The business has a 50-day moving average of $100.73 and a 200-day moving average of $86.56.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be paid a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Thursday, July 23rd. CVS Health’s dividend payout ratio (DPR) is 117.18%.

Analyst Upgrades and Downgrades

CVS has been the topic of several analyst reports. Sanford C. Bernstein lifted their price objective on CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. Wall Street Zen upgraded CVS Health from a “hold” rating to a “buy” rating in a research note on Thursday, July 23rd. Robert W. Baird raised their price target on shares of CVS Health from $92.00 to $94.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 15th. Weiss Ratings raised shares of CVS Health from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, July 20th. Finally, Morgan Stanley increased their price objective on shares of CVS Health from $106.00 to $111.00 and gave the company an “overweight” rating in a research note on Thursday, June 4th. Twenty-one investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $105.67.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS has recently outperformed the broader market, reflecting strong investor momentum following its earnings beat and improving outlook. CVS Health Laps the Stock Market
• Positive Sentiment: Analyst coverage remains broadly constructive, with CVS included among healthcare companies showing favorable indicators ahead of second-quarter 2026 results. Expectations for an earnings beat could support the stock, although execution and margins remain important. Zacks Analyst Blog Highlights CVS Health
• Positive Sentiment: CVS is again identified as one of four medical stocks positioned for a potential second-quarter earnings beat, supported by resilient demand for healthcare products and services. Medical Stocks With the Right Setup for Earnings Beats
• Positive Sentiment: Kate Farms is expanding distribution of its high-protein nutrition shakes into CVS stores, adding another health and wellness product that could modestly increase customer traffic and product breadth. Kate Farms Expands Distribution Into CVS
• Neutral Sentiment: Humana’s upcoming results are drawing attention to Medicare Advantage medical costs and guidance. A favorable report could reinforce sentiment toward health insurers, while cost pressure could have the opposite effect for CVS. Humana Earnings Face High Expectations
• Neutral Sentiment: CVS also highlighted community investments in Massachusetts, caregiving initiatives and recognition for supply-chain work. These support the company’s reputation but are unlikely to materially change near-term earnings. CVS Health Helping Strengthen Communities

Insider Buying and Selling

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Larry Robbins sold 370,462 shares of the stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total transaction of $34,619,673.90. Following the sale, the director directly owned 4,824,799 shares in the company, valued at $450,877,466.55. This trade represents a 7.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,441,551 shares of company stock valued at $323,703,977 over the last quarter. Company insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On CVS Health

A number of institutional investors have recently modified their holdings of CVS. Swiss RE Ltd. acquired a new stake in CVS Health during the fourth quarter worth about $26,000. Caitong International Asset Management Co. Ltd boosted its stake in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 281 shares during the period. Mcguire Capital Advisors Inc. bought a new position in shares of CVS Health during the fourth quarter valued at approximately $28,000. Kemnay Advisory Services Inc. acquired a new stake in shares of CVS Health during the 4th quarter worth approximately $40,000. Finally, Prosperity Bancshares Inc bought a new stake in shares of CVS Health in the 4th quarter worth approximately $43,000. Institutional investors own 80.66% of the company’s stock.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.